01/09/2026
I read it and at first glance, the takeaway sounds exciting: a L. crispatus “postbiotic” improved outcomes when added to standard clobetasol treatment.
We desperately need more research exploring the microbiome, immune environment and v***al health in LS.
But it’s also a great example of why we need to read beyond the headline. The researchers didn’t actually apply L. crispatus to the v***a and the impacts weren’t from a probiotic applied or ingested.
They grew a specific strain of L. crispatus in a lab, then centrifuged and filtered it to remove the bacteria. Participants received 100 μL of the remaining cell-free supernatant alongside clobetasol; the comparison group received clobetasol plus saline.
Essentially, they applied the environment L. crispatus had been growing in, containing products accumulated during fermentation.
So when we read further...
We don’t really know what was in it.
Lactic acid? Other organic acids? Bacteriocins? Peptides? Other metabolites? Altered pH? A combination?
The preparation wasn’t characterised well enough in the methods for us to know :(
So while it’s tempting to conclude:
“L. crispatus is beneficial for lichen sclerosus” that’s not what this research demonstrates.
It tells us that something produced by this particular strain, may have therapeutic potential alongside standard LS treatment.
That isn’t a reason to dismiss the research. Research poses questions, that is the point. And it’s great to see more research into LS, the v***al ecosystem and microbial function. But early research isn’t a clinical conclusion.
Do I use probiotics containing L. crispatus in LS care? Yes, to support specific microbiome changes. This research adds curiosity around potential mechanisms. But for now, we can’t say using L. crispatus improves LS.
Liao H, et al. (2026). Postbiotics originated from Lactobacillus crispatus NCU-31 improves v***ar lichen sclerosus: a randomized, double-blind controlled trial. BMC Microbiology, 26(1), 188.